Life Science Nation Newsletter  |  February 11, 2016  |  Issue 149

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Feb. 4 - Feb. 10)
Seeks Series B-C Opportunities in Innovative Biotech and Medtech
Investing In Precision Medicine And Minimally Invasive Devices
Seeks Med Devices, Instrumentation, and Nanotech
Seeks Platform Technologies with China Angle
In This Issue
LSN Videos
RESI San Francisco 2016 Investors Panel

Video Recap of RESI@TMCx 2015

By Nono Hu, Director of Marketing, LSN

RESI is returning to TMCx on April 11th, and LSN has scheduled two all-day tracks of panel sessions that illuminate every corner of the life science investment landscape. Panels will feature senior, experienced investors from a diversity of investor types - including family offices, VCs, angel syndicates, major global pharma and medical device firms, and more. These investors will explore new investment trends in their sectors, and will share their knowledge and insights with RESI's audience of entrepreneurs. If you'd like to join us at RESI@TMCx to hear the latest on life science financing and book one-on-one meetings with investors, you can register here.

By Lucy Parkinson, Director of Research, LSN

Many major corporations seek to be involved in new health innovations-not just pharma and healthcare players, but also large firms in other industries such as tech and telecoms. Traditionally, the role of large corporations in the healthcare innovation economy has been primarily to act as M&A players as well as development and distribution partners. Many corporations also have corporate VC arms that can engage with companies at an early stage, before M&A would typically occur.

Corporations also make financial investments, and LSN Research has increasingly heard that corporations are seeking to put those financial investments to a strategic purpose. Corporations that are limited partners (LP) in a private equity or venture capital fund are seeing a strategic opportunity in these investments.


By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

Biopharma deal-making value hit a record high in 2015. Where do things go from here? What emerging technologies are big pharma companies now excited about? At the opening of 2016, big pharma executives gathered at RESI San Francisco to shed some light on these questions.

Moderated by Kevin Lynch, Vice President of Scientific Assessment at Abbvie, panelists include:
  • Jason Coloma, Vice President and Global Head Roche Partnering Oncology, Roche Partnering
  • Lesley Stolz, Senior Director of Transaction, Johnson & Johnson Innovation
  • Marc Schwabish, US Head, Pharma Business Development & Licensing, Bayer
  • Tomas Landh, Vice President, Senior Principal Scientist Innovation Sourcing, Novo Nordisk